
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2548228/publications.pdf Version: 2024-02-01



ANAT P TAMBIID

#	Article	IF	CITATIONS
1	The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology. American Journal of Transplantation, 2017, 17, 28-41.	2.6	551
2	Assessing Antibody Strength: Comparison of MFI, C1q, and Titer Information. American Journal of Transplantation, 2015, 15, 2421-2430.	2.6	224
3	Spontaneous Apoptosis of Endometrial Tissue is Impaired in Women with Endometriosis. Fertility and Sterility, 1998, 69, 1042-1047.	0.5	207
4	Cytokine gene polymorphisms in patients infected with hepatitis B virus. American Journal of Gastroenterology, 2003, 98, 144-150.	0.2	207
5	Sensitization in Transplantation: Assessment of Risk (STAR) 2017 Working Group Meeting Report. American Journal of Transplantation, 2018, 18, 1604-1614.	2.6	205
6	Comprehensive Assessment and Standardization of Solid Phase Multiplex-Bead Arrays for the Detection of Antibodies to HLA. American Journal of Transplantation, 2013, 13, 1859-1870.	2.6	187
7	Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantion Society Working Group. Transplantation, 2020, 104, 911-922.	0.5	172
8	The Presence of HLA-Directed Antibodies after Heart Transplantation Is Associated with Poor Allograft Outcome. Transplantation, 2005, 80, 1019-1025.	0.5	146
9	FLOW CYTOMETRIC DETECTION OF HLA-SPECIFIC ANTIBODIES AS A PREDICTOR OF HEART ALLOGRAFT REJECTION1. Transplantation, 2000, 70, 1055-1059.	0.5	126
10	Eplet Mismatch Load and De Novo Occurrence of Donor-Specific Anti-HLA Antibodies, Rejection, and Graft Failure after Kidney Transplantation: An Observational Cohort Study. Journal of the American Society of Nephrology: JASN, 2020, 31, 2193-2204.	3.0	98
11	Emerging Issues With Diagnosis and Management of Fungal Infections in Solid Organ Transplant Recipients. American Journal of Transplantation, 2015, 15, 1148-1154.	2.6	81
12	Perception Versus Reality?: Virtual Crossmatch—How to Overcome Some of the Technical and Logistic Limitations. American Journal of Transplantation, 2009, 9, 1886-1893.	2.6	79
13	The Complexity of Human Leukocyte Antigen (HLA)-DQ Antibodies and Its Effect on Virtual Crossmatching. Transplantation, 2010, 90, 1117-1124.	0.5	75
14	First report on the antibody verification of HLA-DR, HLA-DQ and HLA-DP epitopes recorded in the HLA Epitope Registry. Human Immunology, 2014, 75, 1097-1103.	1.2	75
15	Should HLA Mismatch Acceptability for Sensitized Transplant Candidates Be Determined at the High-Resolution Rather Than the Antigen Level?. American Journal of Transplantation, 2015, 15, 923-930.	2.6	73
16	ROLE OF CYTOKINE GENE POLYMORPHISM IN HEPATITIS C RECURRENCE AND ALLOGRAFT REJECTION AMONG LIVER TRANSPLANT RECIPIENTS 1. Transplantation, 2001, 71, 1475-1480.	0.5	71
17	Sensitization in transplantation: Assessment of risk (STAR) 2019 Working Group Meeting Report. American Journal of Transplantation, 2020, 20, 2652-2668.	2.6	70
18	Extracorporeal photopheresis induces lymphocyte but not monocyte apoptosis. Transplantation Proceedings, 2000, 32, 747-748.	0.3	69

#	Article	IF	CITATIONS
19	Epitope Analysis of HLA-DQ Antigens. Transplantation, 2014, 98, 157-166.	0.5	68
20	Genomic Biomarkers Correlate with HLA-Identical Renal Transplant Tolerance. Journal of the American Society of Nephrology: JASN, 2013, 24, 1376-1385.	3.0	60
21	HLA-Epitope Matching or Eplet Risk Stratification: The Devil Is in the Details. Frontiers in Immunology, 2018, 9, 2010.	2.2	59
22	Nonchimeric HLA-Identical Renal Transplant Tolerance: Regulatory Immunophenotypic/Genomic Biomarkers. American Journal of Transplantation, 2016, 16, 221-234.	2.6	58
23	Donor-Specific HLA Antibodies in Living Versus Deceased Donor Liver Transplant Recipients. American Journal of Transplantation, 2016, 16, 2437-2444.	2.6	53
24	Systemic immunoregulatory and proteogenomic effects of tacrolimus to sirolimus conversion in liver transplant recipients. Hepatology, 2013, 57, 239-248.	3.6	52
25	HLA Diagnostics. Transplantation, 2018, 102, S23-S30.	0.5	51
26	Substituting imputation of HLA antigens for high-resolution HLA typing: Evaluation of a multiethnic population and implications for clinical decision making in transplantation. American Journal of Transplantation, 2021, 21, 344-352.	2.6	51
27	Role of cytokine gene polymorphism and hepatic transforming growth factor β1 expression in recurrent hepatitis C after liver transplantation. Cytokine, 2004, 27, 7-14.	1.4	47
28	The DQ Barrier. Transplantation, 2013, 95, 635-640.	0.5	43
29	The Human "Treg MLR― Immune Monitoring for FOXP3+ T Regulatory Cell Generation. Transplantation, 2009, 88, 1303-1311.	0.5	36
30	Genetic Polymorphism in Platelet-derived Growth Factor and Vascular Endothelial Growth Factor Are Significantly Associated With Cardiac Allograft Vasculopathy. Journal of Heart and Lung Transplantation, 2006, 25, 690-698.	0.3	35
31	Significance of HLA-DQ in kidney transplantation: time to reevaluate human leukocyte antigen–matching priorities to improve transplant outcomes? An expert review and recommendations. Kidney International, 2021, 100, 1012-1022.	2.6	35
32	Allospecific Regulatory Effects of Sirolimus and Tacrolimus in the Human Mixed Lymphocyte Reaction. Transplantation, 2011, 91, 199-206.	0.5	34
33	Innate-like self-reactive B cells infiltrate human renal allografts during transplant rejection. Nature Communications, 2021, 12, 4372.	5.8	34
34	Immunoregulatory profiles in liver transplant recipients on different immunosuppressive agents. Human Immunology, 2009, 70, 146-150.	1.2	29
35	HLA-DQ Barrier. Transplantation, 2013, 96, 1065-1072.	0.5	29
36	Detection of donor-specific antibodies in kidney transplantation. British Medical Bulletin, 2014, 110, 23-34.	2.7	27

#	Article	IF	CITATIONS
37	Assessing the potential of angiotensin II type 1 receptor and donor specific anti-endothelial cell antibodies to predict long-term kidney graft outcome. Human Immunology, 2017, 78, 421-427.	1.2	27
38	Prognostic tools to assess candidacy for and efficacy of antibody-removal therapy. American Journal of Transplantation, 2019, 19, 381-390.	2.6	25
39	The quest to decipher HLA immunogenicity: Telling friend from foe. American Journal of Transplantation, 2019, 19, 2910-2925.	2.6	25
40	Tailoring Antibody Testing and How to Use it in the Calculated Panel Reactive Antibody Era: The Northwestern University Experience. Transplantation, 2008, 86, 1052-1059.	0.5	24
41	Transplantation immunology and the central nervous system. Neurological Research, 2004, 26, 243-255.	0.6	23
42	Antibodies against HLA-DQ α-chain and their role in organ transplantation. Human Immunology, 2009, 70, 410-412.	1.2	22
43	A prospective study evaluating the role of donor-specific anti-endothelial crossmatch (XM-ONE assay) in predicting living donor kidney transplant outcome. Human Immunology, 2013, 74, 1431-1436.	1.2	22
44	Cytokine gene polymorphism in patients with graft-versus-host disease. Transplantation Proceedings, 2001, 33, 502-503.	0.3	21
45	HLA-DQ antibodies. Current Opinion in Organ Transplantation, 2016, 21, 441-446.	0.8	21
46	Platelet-Derived Growth Factor Gene Polymorphism in Recurrent Hepatitis C Infection after Liver Transplantation, 2006, 81, 392-397.	0.5	20
47	Favorable effects of alemtuzumab on allospecific regulatory T-cell generation. Human Immunology, 2012, 73, 141-149.	1.2	19
48	Can solid phase assays be better utilized to measure efficacy of antibody removal therapies?. Human Immunology, 2016, 77, 624-630.	1.2	19
49	Mycophenolic acid inhibits maturation and function of human dendritic cells and B cells. Human Immunology, 2009, 70, 692-700.	1.2	18
50	Updated follow-up of a tolerance protocol in HLA-identical renal transplant pairs given donor hematopoietic stem cells. Human Immunology, 2018, 79, 277-282.	1.2	18
51	The shared epitope phenomenon—A potential impediment to virtual crossmatch accuracy. Clinical Transplantation, 2020, 34, e13906.	0.8	18
52	Common Gamma Chain Cytokines Promote Rapid In Vitro Expansion of Allo-Specific Human CD8+ Suppressor T Cells. PLoS ONE, 2011, 6, e28948.	1.1	17
53	Predicting kidney transplant outcomes with partial knowledge of HLA mismatch. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 20339-20345.	3.3	17
54	Yin and Yan of Cytokine Regulation in Solid Organ Graft Rejection and Tolerance. Clinics in Laboratory Medicine, 2008, 28, 469-479.	0.7	15

#	Article	IF	CITATIONS
55	Unintended Consequences of the New National Kidney Allocation Policy in the United States. American Journal of Transplantation, 2015, 15, 2465-2469.	2.6	15
56	Humoral Human Lung Allograft Rejection by Tissue-Restricted Non-HLA Antibodies. Annals of Thoracic Surgery, 2016, 102, e339-e341.	0.7	15
57	Toward HLA Epitope Matching in Clinical Transplantation. American Journal of Transplantation, 2013, 13, 3059-3060.	2.6	14
58	Real-time qPCR for chimerism assessment in allogeneic hematopoietic stem cell transplants from unrelated adult and double umbilical cord blood. Human Immunology, 2015, 76, 155-160.	1.2	14
59	Incorporating human leukocyte antibody results into clinical practice. Journal of Heart and Lung Transplantation, 2016, 35, 851-856.	0.3	14
60	Current Approaches to Desensitization in Solid Organ Transplantation. Frontiers in Immunology, 2021, 12, 686271.	2.2	14
61	Estimating alloantibody levels in highly sensitized renal allograft candidates: Using serial dilutions to demonstrate a treatment effect in clinical trials. American Journal of Transplantation, 2021, 21, 1278-1284.	2.6	12
62	Successful Bridge to Transplant in a Highly Sensitized Patient With a Complicated Pump Pocket Infection. Journal of Heart and Lung Transplantation, 2008, 27, 568-571.	0.3	11
63	Hiding in Plain Sight-A New Look at HLA Epitopes: A Case Report. American Journal of Transplantation, 2016, 16, 3286-3291.	2.6	10
64	Cytokine Gene Polymorphisms in Patchâ€stage Mycosis Fungoides. Acta Dermato-Venereologica, 2005, 85, 109-112.	0.6	9
65	Virtual crossmatching for deceased donor transplantation: one size does not fit all. Kidney International, 2020, 97, 659-662.	2.6	9
66	IL-4 inhibits P-glycoprotein in normal and malignant NK cells. Human Immunology, 1998, 59, 483-487.	1.2	8
67	Human leukocyte antigen matching in organ transplantation: what we know and how can we make it better (Revisiting the past, improving the future). Current Opinion in Organ Transplantation, 2018, 23, 470-476.	0.8	8
68	Assessment of Virological Contributions to COVID-19 Outcomes in a Longitudinal Cohort of Hospitalized Adults. Open Forum Infectious Diseases, 2022, 9, ofac027.	0.4	8
69	Castleman's disease associated pemphigus. A form of paraneoplastic pemphigus. Journal of the European Academy of Dermatology and Venereology, 1995, 4, 273-279.	1.3	6
70	Cytokine gene polymorphism in liver allograft recipients. Transplantation Proceedings, 2001, 33, 2941-2942.	0.3	6
71	Immunology of the central nervous system. Neurological Research, 2005, 27, 675-678.	0.6	6
72	Role of ELISPOT Assays in Risk Assessment Pre- and Post-Kidney Transplantation. Cells, 2012, 1, 100-110.	1.8	6

#	Article	IF	CITATIONS
73	Harnessing Scientific and Technological Advances to Improve Equity in Kidney Allocation Policies. American Journal of Transplantation, 2017, 17, 3149-3158.	2.6	6
74	Molecular histocompatibility beyond Tears: The next generation version. Human Immunology, 2022, 83, 233-240.	1.2	6
75	Immune monitoring of pediatric heart transplant recipients through serial donor specific antibody testing — An initial experience and review of the literature. Progress in Pediatric Cardiology, 2011, 32, 43-49.	0.2	5
76	Stratifying Patients Based on Epitope Mismatching: Ready for Primetime?. American Journal of Transplantation, 2015, 15, 2021-2022.	2.6	5
77	Impact of SIRPα polymorphism on transplant outcomes in HLAâ€identical living donor kidney transplantation. Clinical Transplantation, 2021, 35, e14406.	0.8	5
78	Development of donor-specific and non-donor-specific HLA-DP antibodies post-transplant: the role of epitope sharing and epitope matching. Clinical Transplants, 2006, , 399-404.	0.2	5
79	Monitoring indirect presentation of alloantigens by utilizing the autologous processing machinery of dendritic cells in-vitro. Journal of Immunological Methods, 2003, 283, 215-223.	0.6	4
80	Auto- and allo-epitopes in DQ alloreactive antibodies. Current Opinion in Organ Transplantation, 2016, 21, 355-361.	0.8	4
81	A blueprint for electronic utilization of ambiguous molecular HLA typing data in organ allocation systems and virtual crossmatch. Human Immunology, 2020, 81, 65-72.	1.2	4
82	Immune and gene expression profiling during tacrolimus to everolimus conversion early after liver transplantation. Human Immunology, 2021, 82, 81-88.	1.2	4
83	Outcomes of repeat kidney transplantation following prior graft failure secondary to BK nephropathy: A singleâ€center retrospective study. Transplant Infectious Disease, 2021, 23, e13672.	0.7	4
84	Hypotension, acidosis, and vasodilatation syndrome post-heart transplantation: lack of association with genetic cytokine profile. Transplantation Proceedings, 2001, 33, 2960-2961.	0.3	3
85	A call to action—The transplant recipient's expectation of precision in transplant medicine. American Journal of Transplantation, 2018, 18, 2845-2846.	2.6	3
86	Measuring human leukocyte antigen alloantibodies: beyond a binary decision. Current Opinion in Organ Transplantation, 2020, 25, 529-535.	0.8	3
87	Accurate eplet identification is necessary for accurate risk assessment. American Journal of Transplantation, 2021, 21, 3504.	2.6	3
88	Requirement of Cognate CD4+ T-Cell Recognition for the Regulation of Allospecific CTL by Human CD4+CD127â^'CD25+FOXP3+ Cells Generated in MLR. PLoS ONE, 2011, 6, e22450.	1.1	3
89	GENETIC CYTOKINE POLYMORPHISM IN LIVER ALLOGRAFT RECIPIENTS Transplantation, 2000, 69, S119.	0.5	2
90	Solid-phase HLA antibody detection methods and risk of renal allograft rejection in children. Transplantation Proceedings, 2001, 33, 403-404.	0.3	2

#	Article	IF	CITATIONS
91	Donor-specific hyporesponsiveness in ELISPOT assay is associated with early recurrence of hepatitis C in liver transplant recipients. Human Immunology, 2005, 66, 21-27.	1.2	2
92	Apples, oranges, and anything in between: In search of the best desensitization therapy. American Journal of Transplantation, 2021, 21, 3825-3826.	2.6	1
93	Castleman's disease associated pemphigus. A form of paraneoplastic pemphigus. , 1995, 4, 273.		1
94	DIFFERENTIAL SENSITIVITY OF RESTING AND IL-2 ACTIVATED NK CELLS TO R-VERAPAMIL1,2. Transplantation, 1996, 62, 1883-1888.	0.5	1
95	Advancing Histocompatibility Testing for Solid Organ Transplantation - What is Needed? A Personal Opinion. Clinical Transplants, 2015, 31, 193-201.	0.2	1
96	Ultraviolet-B irradiation of leukapheresis products: Dose-response relationship with the mixed lymphocyte reaction. Journal of Clinical Apheresis, 1996, 11, 55-60.	0.7	0
97	The Role of HLA-Directed Antibodies in Cardiac Transplant Immunology. Current Cardiology Reviews, 2007, 3, 207-220.	0.6	0
98	Prediction of immunogenic epitopesis it feasible?. Clinical Transplants, 2007, , 203-10.	0.2	0